Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data
Larimar Therapeutics submitted the first module of a rolling BLA for accelerated approval of nomlabofusp and reported positive long‑term open‑label data showing sustained skin FXN increases and clinical improvements.Key Highlights:Original SEC Filing: Larimar Therapeutics, Inc. [ LRMR ] - 8-K - Jun…